On this page
Research Article | Open Access
Volume 14 2022 | None
A CROSS SECTION STUDY TO ASSESS THE RELATIONSHIP BETWEEN SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-19 AND FASTING AND POSTPRANDIAL BLOOD SUGAR LEVELS IN PATIENTS WITH METABOLIC SYNDROME
Aruna .SS, Shanmugasundaram.K, Meenakshi .N, Sowndharya .J, Suganya .K, Dr. K. Krishnaprabha
Pages: 219-227
Abstract
Metabolic syndrome (MetS) refers to the concurrence of several known cardiovascular risk factors, including insulin resistance, obesity, atherogenic dyslipidemia, and hypertension. FGF-19, a peptide with 216 amino acids, including a signal peptide of 22 amino acids was recently introduced as a novel metabolic regulator reversing diabetes mellitus, hepatic steatosis, hyperlipidemia, and adiposity. Aim & Objective: To compare the serum Fibroblast Growth Factor 19 levels of metabolic syndrome patients with healthy individuals. To analyze the correlation between serum FGF 19 and the serum blood glucose levels of patients with MetS. Materials & Methods: A total of 50 patients and 50 controls were included in the study. After obtaining informed consent, anthropometric measures (Height, Weight, BMI & Waist circumference) were taken. Blood investigations such as FGF 19, FBS PPBS were estimated. Statistical Analysis: Student’s t-test was employed for the statistical analysis and data were expressed in terms of mean and standard deviation. ‘p’ value less than 0.05 is considered as statistically significant. Correlation between the measured parameters was assessed using Pearson’s correlation coefficient. Result & Conclusion: Serum levels of FGF 19 were low in patients with metabolic syndrome. The negative relationship obtained between FGF 19 and FBS and PPBS suggests that FGF 19 can be used as a novel marker in assessing the risk of developing metabolic syndrome and also can be used to reduce insulin resistance.
Keywords
Metabolic syndrome, Fibroblast Growth factor 19 (FGF 19), Fasting blood sugar (FBS), Post Prandial Blood Sugar (PPBS)
PDF
141
Views
49
Downloads